Equity intelligence report • June 03, 2026
West Pharmaceutical Services, Inc. has demonstrated financial resilience amid market challenges, reporting robust earnings and healthy growth across its segments. In the latest quarter, the company achieved earnings of $2.47 per share and net sales of $771.3 million, reflecting a significant 13.1% organic growth. Despite successfully navigating economic pressures and a decline in stock price of 31.7% this year, West revised its full-year EPS guidance down to $9.00-$9.15. Earlier reports highlighted strong performances in earlier quarters with increased net income and solid liquidity, indicating a stable financial position amidst ongoing uncertainties.
Click a month on the chart to update the report below.
